Clinical trials and clinical practice - Bridging the gaps in type 2 diabetes: An evidence-based approach to risk factor modification in type 2 diabetes

Australian and New Zealand Journal of Medicine

Volumn 30, Issue 4, 2000, Pages 483-491

  Greenfield, J R ^a   Chisholm, D J ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BEZAFIBRATE; CAPTOPRIL; CHLORPROPAMIDE; FUROSEMIDE; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; INSULIN; METFORMIN; METHYLDOPA; NIFEDIPINE; PRAVASTATIN; PRAZOSIN; SIMVASTATIN; TOLBUTAMIDE;

ADULT; AGED; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; METFORMIN; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINES; PRAVASTATIN; RISK FACTORS;

EID: 0033861932     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2000.tb02056.x     Document Type: Review

References (50)

1. New classification and criteria for diagnosis of diabetes mellitus
2. Pathogenesis of the Insulin Resistance Syndrome (Syndrome X)
3. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
4. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels
5. Diabetes and decline in heart disease mortality in US adults
6. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
7. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project
8. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
9. Effects of aggressive cholesterol lowering and low-dose anti-coagulation on clinical and angiographic outcomes in patients with diabetes: The Post Coronary Artery Bypass Graft Trial
10. Silent myocardial ischaemic in patients with diabetes - Who to screen?
11. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
12. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes
13. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy
14. Statement regarding the University Group Diabetes Program (UGPD) Study
15. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomised prospective 6-year study
16. Glycaemic control retards the progression of albuminuria in NIDDM
17. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
18. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
19. Poorly controlled elderly type 2 diabetic patients: The effects of increasing sulphonylurea dosages or adding metformin
20. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
21. The UK Prospective Diabetes Study
22. Health economic benefits and quality of life during improved glycaemic control in patients with type 2 diabetes
23. Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control
24. Etiology and prevalence of hypertension in diabetic patients
25. Hypertension in Diabetes Study (HDS): I Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications; II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients
26. Initiation and progression of diabetic nephropathy
27. United Kingdom Prospective Diabetes Study 30: Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors
28. Tight blood pressure control and risk of macrovascular and micro-vascular complications in type 2 diabetes: UKPDS 38
29. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39
30. Differences in renal outcomes with ACE inhibitors in type 1 and type 2 diabetic patients: Possible explanations
31. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) Randomised Trial
32. World Health Organisation - International Society of Hypertension Guidelines for the Management of Hypertension
33. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) Randomised Trial
34. Blood pressure control, proteinuria and the progression of renal disease: The modification of diet in renal disease study
35. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23)
36. Diabetes mellitus and hypertension in the elderly: Concomitant hyperlipidaemia and coronary heart disease risk
37. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study
38. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
39. Postprandial dyslipidaemia in a nutshell: Food for thought
40. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
41. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
42. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
43. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: The Bezafibrate Infarction Prevention (BIP) Registry
44. Coronary Heart Disease Incidence in NIDDM Patients in the Helsinki Heart Study
45. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
46. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
47. Apparent discontinuation rates in patients prescribed lipid-lowering drugs
48. The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: A population-based analysis from the health surveys for England 1992-94